Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kronos Bio, Inc.

0.7790
-0.0210-2.62%
Post-market: 0.77900.00000.00%16:00 EDT
Volume:295.00K
Turnover:231.75K
Market Cap:47.50M
PE:-0.54
High:0.8250
Open:0.7800
Low:0.7710
Close:0.8000
Loading ...

Company Profile

Company Name:
Kronos Bio, Inc.
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
10
Office Location:
1300 South El Camino Real,Suite 400,San Mateo,California,United States
Zip Code:
94402
Fax:
- -
Introduction:
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial; and Lanraplenib, a next-generation SYK inhibitor to treat the patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Directors

Name
Position
Arie Belldegrun
Chairman of the Board of Director
Norbert Bischofberger
Director, President and Chief Executive Officer
David Tanen
Director
Elena Ridloff
Director
Jakob Loven
Director
John C. Martin
Director
Joshua Kazam
Director
Otello Stampacchia
Director
Rebecka Belldegrun
Director

Shareholders

Name
Position
Norbert Bischofberger
Director, President and Chief Executive Officer
Barbara Kosacz
Chief Operating Officer and General Counsel
Yasir Al Wakeel
Chief Financial Officer and Head of Corporate Development
Christopher Dinsmore
Chief Scientific Officer
Jorge DiMartino
Chief Medical Officer and Executive Vice President, Clinical Development